Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Sells Thrombosis Drugs to Aspen | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK Sells Thrombosis Drugs to Aspen

To divest Arixtra and Fraxiparine brands for $1.1 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has agreed to sell its thrombosis drug brands and a related factory to Aspen Pharmacare for approximately $1.1 billion. GSK owns an 18.6% stake in Aspen, South Africa’s largest generic drug company.
 
The divestment includes the Arixtra and Fraxiparine brands, whose worldwide sales are declining as new drugs are set to launch. GSK plans to retain the rights to these brands in China, India and Pakistan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters